|
Equillium Inc (NASDAQ: EQ) |
|
Equillium Inc
EQ's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Equillium Inc growth rates, revenue grew
by 37.1 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2504
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.76 %
Equillium Inc net loss decreased from $-4 millions, to $0 millions in III. Quarter 2024,
• More on EQ's Growth
|
|
Equillium Inc realized a net loss in trailing twelve months.
Equillium Inc realized cash reduction of $ -0.53 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
• More on EQ's Valuation
|
|
|
|
|
Equillium Inc realized net loss in trailing twelve months.
Equillium Inc realized cash outflow of $ -0.53per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
Equillium Inc Price to Book Ratio is at 1.15 lower than Industry Avg. of 91.08. and higher than S&P 500 Avg. of 0.01
• More on EQ's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com